"Indoles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Benzopyrroles with the nitrogen at the number one carbon adjacent to the benzyl portion, in contrast to ISOINDOLES which have the nitrogen away from the six-membered ring.
Descriptor ID |
D007211
|
MeSH Number(s) |
D03.633.100.473
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Indoles".
Below are MeSH descriptors whose meaning is more specific than "Indoles".
This graph shows the total number of publications written about "Indoles" by people in this website by year, and whether "Indoles" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 1 | 1 | 2 |
1995 | 0 | 1 | 1 |
1996 | 1 | 1 | 2 |
1997 | 1 | 0 | 1 |
1998 | 0 | 1 | 1 |
1999 | 2 | 4 | 6 |
2000 | 4 | 4 | 8 |
2001 | 3 | 7 | 10 |
2002 | 2 | 1 | 3 |
2003 | 7 | 6 | 13 |
2004 | 10 | 11 | 21 |
2005 | 8 | 10 | 18 |
2006 | 9 | 10 | 19 |
2007 | 13 | 5 | 18 |
2008 | 15 | 13 | 28 |
2009 | 11 | 13 | 24 |
2010 | 13 | 24 | 37 |
2011 | 20 | 27 | 47 |
2012 | 20 | 24 | 44 |
2013 | 27 | 17 | 44 |
2014 | 18 | 24 | 42 |
2015 | 24 | 14 | 38 |
2016 | 18 | 9 | 27 |
2017 | 10 | 10 | 20 |
2018 | 8 | 4 | 12 |
2019 | 2 | 7 | 9 |
2020 | 9 | 4 | 13 |
2021 | 9 | 6 | 15 |
2022 | 0 | 4 | 4 |
2023 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Indoles" by people in Profiles.
-
Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC. J Thorac Oncol. 2024 Mar; 19(3):500-506.
-
Randomized Phase II Trial of Sunitinib or Cediranib in Alveolar Soft Part Sarcoma. Clin Cancer Res. 2023 04 03; 29(7):1200-1208.
-
A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45). J Clin Oncol. 2022 12 01; 40(34):3952-3964.
-
The growing role of rucaparib in contemporary treatment of metastatic prostate cancer: a review of efficacy and guidance for side effect management. Expert Rev Anticancer Ther. 2022 07; 22(7):671-679.
-
Osimertinib, Surgery, and Radiation Therapy in Treating Patients with Stage IIIB or IV Non-Small Cell Lung Cancer with EGFR Mutations (NORTHSTAR). Ann Surg Oncol. 2022 08; 29(8):4688-4689.
-
Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases: data from the randomized controlled INBUILD trial. Respir Res. 2022 Apr 07; 23(1):85.
-
Preexisting TP53-Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With Rucaparib. JAMA Oncol. 2021 Dec 01; 7(12):1772-1781.
-
Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer. Gynecol Oncol. 2021 12; 163(3):490-497.
-
ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer. Int J Gynecol Cancer. 2021 12; 31(12):1589-1594.
-
Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum-based regimen and disease at baseline on efficacy and safety. Cancer Med. 2021 10; 10(20):7162-7173.